"We developed QSant to aid physicians in the early detection of rejection in order to protect patients from an untimely loss of a transplanted kidney" explained NephroSant Founder and University of California professor, Minnie Sarwal, MD, PhD. "Results from this RWD study provide important insights for physicians when interpreting QSant scores. By understanding how these scores relate to a patient's rejection risk, physicians can assess their patients' evolving needs for immunomodulation throughout the continuum of their post-transplant care."
